Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata

Alys Pharmaceuticals Switzerland United Kingdom United States of America Massachusetts

Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications  ALY-101 is formulated as an intradermal injectable for the treatment of Alopecia AreataHealth Authorities in Canada and the United States provided swift CTA & IND approval allowing for efficient dosing of the first patientsView original content:https://www.prnewswire.co.uk/news-releases/alys-pharmaceuticals-announces-dosing-of-first-patient-in-phase-iia-trial-of-aly-101-for-alopecia-areata-302412448.html